Selection criteria utilized for hyperbaric oxygen treatment of carbon monoxide poisoning.
Medical directors of North American hyperbaric oxygen (HBO) facilities were surveyed to assess selection criteria applied for treatment of acute carbon monoxide (CO) poisoning within the hyperbaric medicine community. Responses were received from 85% of the 208 facilities in the United States and Canada. Among responders, 89 monoplace and 58 multiplace chamber facilities treat acute CO poisoning, managing a total of 2,636 patients in 1992. A significant majority of facilities treat CO-exposed patients with coma (98%), transient loss of consciousness (LOC) (77%), ischemic changes on electrocardiogram (91%), focal neurologic deficits (94%), or abnormal psychometric testing (91%), regardless of carboxyhemoglobin (COHb) level. Although 92% would use HBO for a patient presenting with headache, nausea, and COHb 40%, only 62% of facilities utilize a specified minimum COHb level as the sole criterion for HBO therapy of an asymptomatic patient. When COHb is used as an independent criterion to determine HBO treatment, the level utilized varies widely between institutions. Half of responding facilities place limits on the delay to treatment for patients with only transient LOC. Time limits are applied less often in cases with persistent neurologic deficits. While variability exists, majority opinions can be derived for many patient selection criteria regarding the use of HBO in acute CO poisoning.
Hampson
N B
NB
Hyperbaric Medicine Department, Virginia Mason Medical Center, Seattle, Washington 98111, USA.
Dunford
R G
RG
Kramer
C C
CC
Norkool
D M
DM
D002249:Carbon Monoxide Poisoning / Q000097:blood / Q000628:therapy*; D002263:Carboxyhemoglobin / Q000032:analysis; D003128:Coma / Q000139:chemically induced; D006801:Humans; D006931:Hyperbaric Oxygenation; D017202:Myocardial Ischemia / Q000139:chemically induced; D009422:Nervous System Diseases / Q000139:chemically induced; D018579:Patient Selection; D013997:Time Factors
D002263:Carboxyhemoglobin